{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:43:42Z","timestamp":1793573022964,"version":"4.5.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST). To address the real-world implications of the FVIII mimetic antibody, emicizumab, and the role of IST, we retrospectively collected de-identified data on 62 patients with AHA who were treated off-label with emicizumab for a median of 10\u00a0weeks at 12 US-based hemophilia treatment centers. Most patients (95.2%) had acute bleeding at diagnosis, and 62.9% had partial or no control of bleeds despite the use of hemostatic agents at the time emicizumab was started. The main reason for initiating emicizumab was outpatient bleeding prophylaxis. After initiation of emicizumab, 87.1% had no additional bleeds. There were 6 breakthrough bleeds (2 spontaneous) in 5 patients and no fatal bleeding events during maintenance emicizumab treatment. The mean breakthrough bleed rate per patient-week was 0.02 (95% confidence interval, 0.0-0.03) during the first 12\u00a0weeks of emicizumab for the 55 patients with at least 12\u00a0weeks of follow-up. Of these patients, 92.7% received IST and 74.5% were prescribed rituximab-based regimens. Complete resolution of inhibitor and normalization of FVIII levels occurred in 56% overall and in 63% of the patients treated with rituximab. Overall, the median time to discontinuation of emicizumab and IST was 18\u00a0weeks. Two patients had thrombotic events while on emicizumab, but no adverse events were attributed to emicizumab and there were no infections attributed to IST. Emicizumab provides effective outpatient bleeding prophylaxis for AHA, and concurrent IST may further mitigate bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013882","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T13:53:20Z","timestamp":1727963600000},"page":"5896-5905","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-5106","authenticated-orcid":false,"given":"Jacqueline N.","family":"Poston","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Larner College of Medicine at The University of Vermont, Burlington, VT"},{"name":"2Division of Clinical Pathology, Department of Pathology and Laboratory Medicine, Larner College of Medicine at The University of Vermont, Burlington, VT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Bryan","sequence":"additional","affiliation":[{"name":"3Washington Center for Bleeding Disorders, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-6322","authenticated-orcid":false,"given":"Annette","family":"von Drygalski","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadhim","family":"Al Banaa","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, University of California San Diego, San Diego, CA"},{"name":"5Department of Hematology\/Oncology, Beaumont Hospital, Royal Oak, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Y.","family":"Zhou","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric","family":"Parnes","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-215X","authenticated-orcid":false,"given":"Evan C.","family":"Chen","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Khan","sequence":"additional","affiliation":[{"name":"7The Jimmy Everest Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Oklahoma Health Sciences, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ellsworth","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Cafuir","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Walsh","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Medical Oncology, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-0240","authenticated-orcid":false,"given":"Miguel A.","family":"Escobar","sequence":"additional","affiliation":[{"name":"11McGovern Medical School and Gulf States Hemophilia and Thrombophilia Center, University of Texas Health Science Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-6173","authenticated-orcid":false,"given":"James F.","family":"Wu","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Malec","sequence":"additional","affiliation":[{"name":"13Versiti Comprehensive Center for Bleeding Disorders, Versiti Blood Center of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0599-5724","authenticated-orcid":false,"given":"Craig M.","family":"Kessler","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology, Department of Medicine, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4176-9110","authenticated-orcid":false,"given":"Maissaa","family":"Janbain","sequence":"additional","affiliation":[{"name":"15Section of Hematology\/Oncology, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6547-5240","authenticated-orcid":false,"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[{"name":"3Washington Center for Bleeding Disorders, Seattle, WA"},{"name":"16Division of Hematology\/Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"issue":"4","key":"2024112214505869400_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2024112214505869400_bib2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG"},{"issue":"4","key":"2024112214505869400_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"issue":"2","key":"2024112214505869400_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI -1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"3","key":"2024112214505869400_bib5","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2024112214505869400_bib6","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024112214505869400_bib7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jth.14746","article-title":"An anti-factor IXa\/factor X bispecific antibody, emicizumab, improves ex\u00a0vivo coagulant potentials in plasma from patients with acquired hemophilia A","volume":"18","author":"Takeyama","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"16","key":"2024112214505869400_bib8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024112214505869400_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024112214505869400_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemophilia"},{"issue":"3","key":"2024112214505869400_bib11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A\u00a0prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2024112214505869400_bib12","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024112214505869400_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2021-148040","article-title":"Emicizumab for the treatment of acquired hemophilia A: a multicenter US case series","volume":"138","author":"Poston","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024112214505869400_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2024112214505869400_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inf"},{"key":"2024112214505869400_bib16","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J\u00a0Biomed Inf"},{"issue":"7","key":"2024112214505869400_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"2024112214505869400_bib18","article-title":"Anticoagulation for stroke prevention after restoration of haemostasis with emicizumab in acquired haemophilia A","volume":"17","author":"Al-Banaa","year":"2021","journal-title":"European Journal of Case Reports in Internal Medicine"},{"issue":"5","key":"2024112214505869400_bib19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"issue":"18","key":"2024112214505869400_bib20","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"Simon","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024112214505869400_bib21","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2024112214505869400_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5896\/2314986\/blooda_adv-2024-013882-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5896\/2314986\/blooda_adv-2024-013882-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T09:51:10Z","timestamp":1732269070000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/22\/5896\/517940\/Real-world-impact-of-emicizumab-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":22,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013882","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}